By Dr Charles Edo de Bock

Journal articles

Sadeqzadeh E; De Bock CE; Wojtalewicz N; Holt JE; Smith ND; Dun MD; Schwarte-Waldhoff I; Thorne RF, 2014, 'Furin processing dictates ectodomain shedding of human FAT1 cadherin', Experimental Cell Research, 323, pp. 41 - 55, http://dx.doi.org/10.1016/j.yexcr.2014.02.012

Wojtalewicz N; Sadeqzadeh E; Weiß JV; Tehrani MM; Klein-Scory S; Hahn S; Schmiegel W; Warnken U; Schnölzer M; De Bock CE; Thorne RF; Schwarte-Waldhoff I, 2014, 'A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding', PLoS ONE, 9, pp. e90461, http://dx.doi.org/10.1371/journal.pone.0090461

Sadeqzadeh E; De Bock CE; Thorne RF, 2014, 'Sleeping Giants: Emerging Roles for the Fat Cadherins in Health and Disease', Medicinal Research Reviews, 34, pp. 190 - 221, http://dx.doi.org/10.1002/med.21286

Sadeqzadeh E; de Bock CE; O'Donnell MR; Timofeeva A; Burns GF; Thorne RF, 2014, 'FAT1 cadherin is multiply phosphorylated on its ectodomain but phosphorylation is not catalysed by the four-jointed homologue', FEBS Letters, http://dx.doi.org/10.1016/j.febslet.2014.08.014

Ardjmand A; de Bock CE; Shahrokhi S; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2013, 'Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia', Hematology, 18, pp. 315 - 322, http://dx.doi.org/10.1179/1607845413Y.0000000080

De Bock CE; Ardjmand A; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Nelmes G; Stewart D; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2012, 'The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia', Leukemia, 26, pp. 918 - 926, http://dx.doi.org/10.1038/leu.2011.319

Dong L; Jiang CC; Thorne RF; Croft A; Yang F; Liu H; De Bock CE; Hersey P; Zhang XD, 2011, 'Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress', Oncogene, 30, pp. 3716 - 3726, http://dx.doi.org/10.1038/onc.2011.87

Sadeqzadeh E; De Bock CE; Zhang XD; Shipman KL; Scott NM; Song C; Yeadon T; Oliveira CS; Jin B; Hersey P; Boyd AW; Burns GF; Thorne RF, 2011, 'Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products', Journal of Biological Chemistry, 286, pp. 28181 - 28191, http://dx.doi.org/10.1074/jbc.M111.234419

De Bock CE; Garg MB; Scott N; Sakoff JA; Scorgie FE; Ackland SP; Lincz LF, 2011, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 11, pp. 307 - 314, http://dx.doi.org/10.1038/tpj.2010.43

Thorne RF; Ralston KJ; de Bock CE; Mhaidat NM; Zhang XD; Boyd AW; Burns GF, 2010, 'Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum', Biochimica et Biophysica Acta - Molecular Cell Research, 1803, pp. 1298 - 1307, http://dx.doi.org/10.1016/j.bbamcr.2010.07.002

De Bock CE; Lin Z; Mekkawy AH; Byrne JA; Wang Y, 2010, 'Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion', International Journal of Oncology, 36, pp. 1155 - 1163, http://dx.doi.org/10.3892/ijo-00000598

De Bock CE; Lin Z; Mekkawy AH; Byrne JA; Wang Y, 2010, 'Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion', International Journal of Oncology, 36, pp. 1155 - 1163, http://dx.doi.org/10.3892/ijo_00000598

Mekkawy AH; De Bock CE; Lin Z; Morris DL; Wang Y; Pourgholami MH, 2010, 'Novel protein interactors of urokinase-type plasminogen activator receptor', Biochemical and Biophysical Research Communications, 399, pp. 738 - 743, http://dx.doi.org/10.1016/j.bbrc.2010.08.010

Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; DeBock CE; Thorne RF; Allen J; Hesey P; Zhang XD, 2008, 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, 68, pp. 6708 - 6717, http://dx.doi.org/10.1158/0008-5472.CAN-08-0349

Mhaidat NM; Thorne RF; de Bock CE; Zhang XD; Hersey P, 2008, 'Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III β-tubulin levels', FEBS Letters, 582, pp. 267 - 272, http://dx.doi.org/10.1016/j.febslet.2007.12.014

Tassabehji M; Fang ZM; McGaughran J; Zhao Z; De Bock CE; Howard E; Malass M; Donnai D; Diwan AD; Manson FD; Murrell DF; Clarke RA, 2008, 'Mutations in GDF6 are associated with vertebral segmentation defects in klippel-feil syndrome', Human Mutation, 29, pp. 1017 - 1027

Molloy TJ; De Bock CE; Wang Y; Murrell GA, 2006, 'Gene expression changes in SNAP-stimulated and iNOS-transfected tenocytes-expression of extracellular matrix genes and its implications for tendon-healing', Journal of Orthopaedic Research, 24, pp. 1869 - 1882

De Bock CE; Lin Z; Itoh T; Morris DL; Murrell GA; Wang Y, 2005, 'Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells', FEBS Journal, 272, pp. 3572 - 3582

de Bock CE; Wang Y, 2004, 'Clinical Significance of Urokinase‐Type Plasminogen Activator Receptor (uPAR) Expression in Cancer', ChemInform, 35, http://dx.doi.org/10.1002/chin.200414278

De Bock CE; Wang Y, 2004, 'Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer', Medicinal Research Reviews, 24, pp. 13 - 39

Xia W; De Bock CE; Murrell GA; Wang Y, 2003, 'Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing', Journal of Orthopaedic Research, 21, pp. 819 - 825

Gieseg MA; De Bock C; Turner P; Ferguson LR; Denny WA, 2002, 'The effect of DNA-alkylating agents on gene expression from two integrated reporter genes in a mouse mammary tumor line', Anti-Cancer Drugs, 13, pp. 271 - 280, http://dx.doi.org/10.1097/00001813-200203000-00009

Gieseg MA; De Bock C; Ferguson LR; Denny WA, 2001, 'Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033', Anti-Cancer Drugs, 12, pp. 683 - 690, http://dx.doi.org/10.1097/00001813-200109000-00007

Back to profile page